MNTA: This is so important to me, that I think it appropriate to post the most relevant quotes from last week (2/13 & 2/14) from Craig Wheeler irt the M118 molecule. I have not found him to be a boaster; however, take the comments with the appropriate grain of m-salt:
"In October 2007, we reported the top line results from our Phase 1 study of intravenously administered M118 and initiated the Phase 2a program evaluating the safety and feasibility of using M118 as procedural anticoagulant during elective PCI or angioplasty. This early human data continues to exhibit the characteristics we have expected based on our design of the drug."
"...Every day when we see more information on this program, we are becoming more and more bullish on the potential of this compound..."
"...I couldn't be more pleased."
"(the M118 molecule is behaving) exactly as we hoped it would behave."
--(Think about that comment: "exactly as we hoped it would behave.")
"...which means we have the potential ability to come into this market at a pretty good price point..."
In summary, I find these comments to be striking coming from this particular CEO, and keeping in mind that he seems to be implying that real-time data from the EMINENCE trial is known by MNTA. There has not been one shred of "if the PIIa succeeds we would like to partner." Nope, it's been more like "well, we would like $1B upfront after PIIa." {with laughter for the analyst's question}
I've been bitten before, but Craig Wheeler doesn't remind me of P.T. Barnum.
Market Data 
Markets 
AI
